Improving treatment outcome in paediatric acute lymphoblastic leukaemia by minimal residual disease detection and pharmacokinetics

通过微小残留病检测和药代动力学改善儿童急性淋巴细胞白血病的治疗结果

• 批准号: nhmrc : 1009087
• 负责人: A/Pr Rosemary Sutton
• 金额: $ 40.66万
• 依托单位: The University of New South Wales
• 依托单位国家: 澳大利亚
• 项目类别: NHMRC Project Grants
• 财政年份: 2011
• 资助国家: 澳大利亚
• 起止时间: 2011-01-01 至 2013-12-31
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/improving-treatment-outcome-detection-pharmacokinetics/109370
• 关键词: Improving; treatment; outcome; paediatric; acute

The main objective of this project is to make substantial improvements in the treatment of patients with childhood leukaemia by greater use of molecular diagnostics to measure minimal residual disease (MRD) and pharmacokinetic testing to determine the effectiveness of a key chemotherapy drug (PEG-L-Asparaginase) in Australian patients enrolled on an international clinical trial which has been designed to reduce the incidence of both relapses and long term side-effects.

该项目的主要目标是通过更多地使用分子诊断来测量最小残留疾病（MRD）和药代动力学测试来确定一种关键化疗药物（peg - l -天冬酰胺酶）在参加国际临床试验的澳大利亚患者中的有效性，从而大大改善儿童白血病患者的治疗，该试验旨在减少复发和长期副作用的发生率。